Mice deficient in IL-1beta manifest impaired contact hypersensitivity to trinitrochlorobenzone by unknown
Mice Deficient in IL-I~ Manifest Impaired 
Contact Hypersensitivity to Trinitrochlorobenzene 
By Laurie P. Shornick,* Pietro De Togni,*~ Sanjeev Mariathasan)l 
Joseph Goellner, SJena Strauss-Schoenberger,1 Robert W. Karr,1 
Thomas A. Ferguson,*S and David D. Chaplin*ll 
From the "Department of Internal Medicine and Center  for Immunology, *Department of 
Ophthalmology, g  Department of Pathology, and n  Howard Hughes Medical Institute, Washington 
University School of Media'ne, St. Louis, Missouri 63I 10; and 'lDepartment of Immunology, G.D. 
Searle and Company, St. Louis, Missouri 63198 
Summary 
Mice rendered deficient in IL-1[3 by gene targeting in embryonic stem cells develop and grow 
normally in a protected laboratory environment. Endotoxin-stimulated peritoneal macrophages 
from IL-l~-deficient mice showed normal synthesis and cellular release  of IL-lct after treat- 
ment with 5 mM ATP demonstrating that IL-113 is not necessary for expression and release of 
the IL-lot isoform. Mice deficient in IL-I~ showed unaltered sensitivity to endotoxic shock, 
with or without pretreatment with D-galactosamine. In contrast, IL-lJ3-deficient mice showed 
defective  contact  hypersensitivity  responses  to  topically  applied  trinitrochlorobenzene 
(TNCB). This defect could be overcome either by application of very high doses of sensitizing 
antigen, or by local intradermal injection of recombinant IL-1[3 immediately before antigen 
application. These data demonstrate an essential role for IL-1[3 in contact hypersensitivity and 
suggest that IL-1{3 acts early during the sensitization phase of the response. They suggest an im- 
portant role for 1I.-1(3 in initiation of the host response at the epidermal barrier. 
T 
he  potent  proinflammatory  cytokine  interleukin-1 
(IL-1) is synthesized in two isoforms (designated IL-la 
and  IL-1[3)  encoded  by  distinct,  chromosomally linked 
genes (1-3).  Both forms of IL-1 are synthesized as 31-kD 
intracellular precursors that are cleaved to the 17-kD ma- 
ture cytokines found in culture supernatants and extracellu- 
lar fluids  (4). The  maturation  of the  IL-la  precursor  is 
thought to be dependent on the calcium-activated protein- 
ase calpaln (5), whereas the maturation of the IL-1[~ pre- 
cursor is dependent on the cysteine proteinase IL-lJ~-con- 
verting enzyme (ICE) 1 (6). Two cell surface  receptors for 
IL-1 have been defined (7-9),  designated IL-1RI and IL- 
lP,  II. Mature IL-la and IL-lJ3 bind similarly to these two 
defined receptors (10) and, consequently, demonstrate the 
same activities in a broad range of in vitro and in vivo bio- 
logical systems. 
The ability of the IL-1 proteins to modulate the normal 
and pathological physiology of essentially all  tissues  is  a 
1Abbreviations used in this paper: ES, embryonic  stem; ICE, IL-l[~-convert- 
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consequence of the broad expression of the defined IL-1 
receptors. Based on studies of the action of the cytokines in 
vitro  and following their  administration to  experimental 
animals in vivo, IL-1 is thought to potentiate inflammatory 
responses  and to promote tissue  repair (4). These studies, 
however, define only the potential actions of IL-1 in nor- 
mal and pathological responses.  Studies defining the physi- 
ological responses  in which IL-1 acts in an obligatory fash- 
ion remain incomplete. Definition of the essential functions 
oflL-1 in vivo is complicated by the fact that many of the 
actions of IL-1 defined in vitro are shared with other cy- 
tokines, particularly with IL-6, tumor necrosis factor (TNF) 
and lymphotoxin (LT)  (4,  11,  12). Furthermore, in many 
tissues  these  cytokines  regulate  each  other's  expression, 
forming  a  potentially  complex  and  interactive  cytokine 
network (13). 
There has been considerable progress in defining the es- 
sential functions oflL-1 in vivo by using either neutralizing 
monoclonal antibodies (against IL-1 or against the IL-1 re- 
ceptors)  (14-16),  soluble IL-1 receptors (17),  or the natu- 
rally occurring IL-1  receptor  antagonist  (IL-lra)  (18) to 
block  IL-1  action in  experimental animal models.  Using 
these approaches, IL-1 has been implicated as a significant 
mediator in the generation of fever (19) and acute inflam- 
matory responses  (20). IL-1 also contributes fundamentally 
in  the  normal host response  against infection by Listeria 
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pendent on actions of this cytokine in the recruitment of 
neutrophils and in the activation of macrophages (21). 
Few studies of this nature, however, have demonstrated 
unique roles for either of the IL-1 agonist isoforms. Studies 
by Geiger et al. (22) and Van den Berg et al. (23) have sug- 
gested a selective role for IL-113 in the initiation and pro- 
gression of collagen-induced arthritis in mice. A fundamental 
action of IL-1 has also been suggested in a transgenic model 
ofpetipheral arthritis due to aberrant expression of  TNFct (24). 
An additional selective role for IL-1[3 has been proposed 
in the development of contact hypersensitivity responses in 
the skin (25, 26).  Contact sensitizers  increase the levels of 
mRNA for several cytokines in the skin, including IL-lct, 
IL-113, and TNFcx. IL-113 m.R2qA  is increased first,  being 
detected within 15 min aRer application of the sensitizing 
agent. Selective depletion of individual epidermal cell pop- 
ulations  suggests  that  Langerhans  cells  are  the  primary 
source  of IL-113, and  that  keratinocytes are  the  primary 
source oflL-lcx (27). The regulatory specificity oflL-l[3 in 
contact hypersensitivity responses was suggested by studies 
in which intradermal injection of monoclonal anti-murine 
IL-113 antibodies prevented primary sensitization (26). In con- 
trast, anti-IL-lct antibodies did not interfere with sensitization. 
New insights  into the in vivo action oflL-l[3 have come 
from studies  using mice rendered genetically deficient in 
this cytokine by gene targeting in embryonic stem cells (28). 
These studies have demonstrated that IL-113 is an essential 
mediator of the systemic response following subcutaneous 
injection of turpentine. Mice deficient in IL-I[~ failed to 
demonstrate the typical anorexic and febrile responses that 
follow this maneuver. They also showed an impaired tur- 
pentine-induced acute phase response, with failure of in- 
duction of plasma IL-6. Plasma IL-6 levels were, however, 
indistinguishable in normal and IL-l[3-deficient mice after 
challenge  with  lipopolysaccharide  (LPS),  indicating  that 
there was no absolute defect in IL-6 production. This study 
demonstrated a  selective role for IL-113 in  activating the 
systemic response to subcutaneous injection of turpentine, 
and established unequivocally that IL-113 and IL-lct can act 
independently in vivo. 
We report here the independent production of a mouse 
strain  deficient in  IL-113, and experiments demonstrating 
an essential  action of IL-113 in contact hypersensitivity re- 
sponses to trinitrochlorobenzene (TNCB).  This action of 
IL-113 appears to be expressed at the  early times of local 
sensitization,  as  normal  contact hypersensitivity responses 
can  be  restored by intradermal  injection of recombinant 
murine IL-113 locally immediately before the application of 
the sensitizing antigen.  These data establish  a critical role 
for IL-113 in the initiation of  the systemic immune response 
to this agent after sensitization at epidermal surfaces. 
Materials and Methods 
IL-lfl Targeting Vector.  A 4.6-kb EcotLI to EcoI~V fragment 
containing exons 1 through 5 of the IL-113 gene was subcloned 
from cosmid [37.1 (2) into EcolLI- and SmaI-digested pUC119. 
A Sail site (underlined) and a termination  codon (italics) were in- 
troduced into exon 4 using the method of Kunkel  (29) and the 
mutagenesis oligonucleotide 5'-GGC TGC TTC CAA ACC GTC 
GAC CTG GGC TGA CCT GAT-3'. The altered 4.6-kb IL-113 
fragment was removed from this vector by digestion with BamHI 
and  was  introduced into  the BamHI site  of pBluescript  KS+ 
(Stratagene, La Jolla, CA) containing the HSV-thymidine  kinase 
gene under the control of a polyoma promoter and  enhancer 
(30). Finally, a 1.6-kb XhoI fragment encoding neomycin resis- 
tance (neo  r) under the control of the pgk promoter (31) was in- 
serted into the Sail site in the opposite transcriptional orientation 
compared to the IL-l[3 gene. The final targeting vector was 10.6 
kb and contained 3.3-kb  of sequence homologous  to the IL-113 
locus in its 5'  arm and  1.3 kb in its 3'  arm. Plasmid DNA for 
electroporation was linearized by digestion with NotI. 
Generation oflL-1~-d~qcientMice.  D3 embryonic stem cells (pro- 
vided by T. Doetschman,  University  of Cincinnati,  OH) were 
electroporated with the linearized IL-113 targeting vector as pre- 
viously described (32). Homologous recombinants were selected 
using 250 p~g/ml G418 (GIBCO BILL, Gaithersburg, MD) and 2 
IzM ganciclovir (Cytovene|  Syntex Laboratories, Paio Alto, CA) 
and screened by Southern blotting. 
Southern Blotting.  DNA was isolated from the livers of wild- 
type, heterozygous, and IL-l[3-deficient mice or from expanded 
colonies oftransfected D3 cells as previously described (2, 33) and 
was  digested  overnight  with  BamHL  Digested  DNA  samples 
were fractionated on a 1% agarose gel, blotted to a nylon falter 
and hybridized (34) with a 32p-labeled probe from intron 5. The 
probe was a 352-bp fragment amplified from the IL-113  locus us- 
ing the polymerase chain reaction  (PCIL), using the following 
oligonucleotide primers: CTC TCT TCC ATA ATA ACA AG 
and GCA GGA GGC AGG TAG AAC TC. It was labeled with 
[32p]dCTP using the random priming method (Amersham Corp., 
Arlington Heights, IL). 
Northern Blotting.  Peritoneal  exudate  cells (PEC) were elic- 
ited with thioglycollate broth and plated at 1.5 ￿  106 ceUs/ml as 
previously described (35). Following adherence overnight, the PEC 
were incubated either in the presence or absence of 1 p~g/ml E. coli 
LPS for 4 h, and RNA was isolated using a modification of the 
guanidinium isothiocyanate/CsC1 method (36) as described (35). 
Hybridization was with 32p-labeled near full-length fragments of 
the IL-lot (37) and IL-113 (38) cDNAs labeled using the random 
priming method. 
Metabolic Labeling and Imraunoprecipitation.  PEC harvesting, cul- 
ture,  pulse-chase labeling using 3SS-met, and immunoprecipita- 
tion were performed as previously described (15) with hamster 
anti-mouse IL-lct and anti-mouse IL-1B monoclonai antibodies 
161.1 (14) and B122 (15). 
Measurement oflL-1 by ELISA.  IL-lct and IL-1B were mea- 
sured using commercial ELISA kits (Genzyme, Cambridge, MA) 
according  to  the manufacturer's  instructions.  PEC were incu- 
bated and culture supematants and cell lysates were prepared as 
described for metabolic labeling and immunoprecipitation.  CeU 
lysates were centrifuged for 10 rain at 4~  in an Eppendoffmodel 
5414 microcentrifuge before assay. The limit of sensitivity of the 
IL-lot ELISA was 15 pg/ml, and of  the IL-113  ELISA 10 pg/ml. 
Flow Cytometry.  Single  cell suspensions from spleen, thymus, 
and lymph nodes were prepared from a 7-wk-old IL-l[3-deficient 
mouse and its wild-type littermate. Dead ceils and erythrocytes were 
removed  by centrifugation over Ficoll-Hypaque  (Sigma Chem. 
Co., St. Louis, MO) and washed in flow cytometry  buffer (HBSS 
containing  1  mM  Hepes,  pH  7.35 [GIBCO  BILL], and  0.2% 
1428  Impaired  Contact Hypersensitivity  in IL-l~-deficient Mice Figure 1.  (a) Targeted disruption  of the gene encoding murine IL-113. Structure  of  the targeting vector, the gene encoding the wild-type mouse IL-113 
locus and the predicted  targeted allele. Black boxes indicate exons of the IL-113 gene. The gene was inactivated by insertion  ofa neo  r cassette into exon 
4. This introduces an in-frame stop codon. Homologous recombination of  this construct with the IL-1 [3 locus alters the length of  SstI and BamHl restric- 
tion fragments detected with the 3' external probe (stippled box). 13, BamHI; S, SstI. The lengths of the indicated restriction fragments are in kilobases. (b) 
Southern blot analysis of  the IL-1[3 locus in IL-1[3 +/+, IL-1[3 +/-, and IL-113  -/- mice. DNA was isolated from liver and digested overnight with BamHI. 
Hybridization  probes were the 3' external IL-113 probe and a fragment of the neo  r gene labeled with [a2P]dCTP, as indicated.  (c) Northern blot of  KNA 
isolated from LPS-stimulated  PEC from IL-1B +/+, IL-113  +/-, and IL-lf3 -/-  mice.  Thioglycollate-elicited  PEC were allowed to adhere  overnight and 
were then stimulated with LPS for 4 h. Hybridization  probes were near full-length 32p-labeled cDNA fragments oflL-lcx and IL-113 as indicated. 
sodium azide). 1 ￿  106 cells were stained for 30 min at 4~  with the 
following  antibodies:  phycoerythrin-conjugated  anti-mouse 
L3T4 (Becton Dickinson, Bedford,/VIA), FITC-conjugated anti- 
mouse Lyt-2 (Becton Dickinson), phycoerythrin-conjugated anti- 
mouse CD45R (PharMingen,  San Diego, CA), and FITC-conju- 
gated  anti-mouse  CD3-epsilon  (PharMingen).  The  cells  were 
then  washed  three  times with  flow cytometry  buffer and  fixed 
with 2% paraformaldehyde in PBS. Cells were analyzed on a Bec- 
ton Dickinson FACScan  |  using the Lysis I program. 
1429  Shomick et al. 
Endotoxic Shock.  Endotoxic shock was induced by two differ- 
ent protocols.  In the  first,  age-matched  mice were  injected i.p. 
with 20 mg D-galactosamine and  10 g~g E.  coli LPS (0111:B4)  in 
0.5 ml sterile PBS. Lethal responses were always observed within 
the  first  12  h  following injection.  Mice  that  survived were  ob- 
served for 1 wk and appeared to recover completely. In the sec- 
ond protocol,  8-12-week-old mice received 1.5 mg LPS  (0127: 
B8) in 0.5 ml sterile PBS by i.p. injection. 
Contact Hypersensitivity.  Reactivity to TNCB was determined using a modification of the method of Ferguson et al. as previ- 
ously described (39). Briefly, 8-12-week-old IL-113 deficient mice 
and their wild-type littermates were prepared by shaving their ab- 
domens and then varying doses of TNCB  (Eastern Chemical, 
Smithtown, NY) were applied in 25 ~  olive oil/acetone (1:3). 5 d 
later, the mice were challenged by injection of 33/~1 of 10 mM 
TNBS (Sigma) into the right footpad. The same volume of PBS 
was injected into the left footpad as a negative control. 24 h hter, 
footpad swelling was measured by a blinded  observer and ex- 
pressed as the thickness of the right footpad minus the thickness 
of the left footpad. Where indicated, recombinant murine IL-113 
was injected intradermaUy at the sensitization site immediately 
before the  application of TNCB. 1Leactivity  to oxazolone was 
determined as previously described (28). 
Lymphocyte Proliferative Responses.  Lymphocytes were isohted 
from the axillary and inguinal lymph nodes of TNCB-sensitized 
mice.  Cells from four mice  treated  in a  similar fashion were 
pooled and 5 ￿  10  s cells were cultured in triplicate in 96-well 
flat-bottom  microtiter  phtes in  100  IX1 R.PMI 1640 (GIBCO 
BILL) with 10% heated fetal calf  serum, glutamine, 2-mercaptoeth- 
anol, penicillin, and streptomycin. Each well also contained from 
0-4  ￿  10  s 2,4,6-trinitrophenyl  (TNP)-coupled,  mitomycin- 
C-treated spleen cells from wild-type sv129 mice (Jackson Labo- 
ratories, Bar Harbor, ME). After 78 h of culture, 1 mCi (37 kBq) 
of [3H]thymidine (DuPont  NEN,  Boston,  MA)  was added to 
each well, and 18 h later, cells were harvested using a PhD cell 
harvester (Cambridge Technology, Inc., Watertown,  MA), and 
incorporation of radioactivity determined by liquid scintillation 
counting as previously described (39). 
Results and Discussion 
Generation  oflI.,-l~-deficient  Mice.  The IL-I[~ gene is en- 
coded in seven exons (40). To create a mouse strain carry- 
ing a null allele at this locus, we generated a targeting vector 
in which exon 4 was interrupted by insertion of the PGK- 
neo sequence (31). This introduced an in frame termination 
codon upstream of the ICE cleavage site encoded in exon 
5,  precluding the translation of the receptor-binding do- 
main of the protein.  The vector contained 3.4 kb of se- 
quence homologous to the IL-113 gene upstream of the neo 
cassette,  and 1.1 kb of homologous sequence downstream 
of neo, with HSV-tk included upstream of the 3.4-kb arm 
for negative selection (30) (Fig. 1 a). After homologous re- 
combination in embryonic stem (ES) cells, the wild-type 
5.9-kb  IL-113 BamHI fragment was  replaced by a  7.5-kb 
fragment in the targeted allele (Fig. 1 b). 
This construct was introduced into D3 ES cells by dec- 
troporation and homologous recombinants were selected 
using  ganciclovir  and  G418.  Homologous  recombinants 
were detected at a frequency of ,'ol  in 100  double drug- 
resistant colonies. One targeted D3 line passed the targeted 
allele  through  the  germ  line.  Matings  of heterozygous 
IL-113--deficient mice confirmed the results of Zheng et al. 
(28) that homozygous mutant mice were obtained at a fre- 
quency ofl in 4, indicating that a normal IL-113 gene is not 
required for successful embryonic development. The struc- 
ture of the targeted locus was confirmed by Southern blot- 
ting using as the probe a fragment of the IL-113 gene de- 
rived  from a  portion  of the  5th  intron  external  to  the 
targeting vector (Fig.  1 a). Hybridization with a neo probe 
confirmed that there was  only a  single integration event 
(Fig. 1 b). Again confirming the results ofZheng et al. (28), 
IL-113-deficient mice  displayed a  grossly  normal pheno- 
type, demonstrating that IL-113 is not essential for posmatal 
development. 
The development of  cells of  the hematopoietic lineage was 
assessed by flow cytometry and histological analysis. IL-113- 
deficient and wild-type mice did not differ significantly in 
the numbers of peripheral blood erythrocytes, lymphocytes, 
monocytes, neutrophils, or platelets (data not shown). Sim- 
ilarly,  the cell content and architecture of the spleen and 
thymus were grossly similar in IL-l~-deficient and wild- 
type mice (data not shown). 
Evaluation oflL-1  Expression.  Functional ablation of the 
IL-113 gene was confirmed by Northern blotting, immuno- 
precipitation, and ELISA. PEC were elicited by i.p. injec- 
tion of thioglycollate. 3 d afEer thioglycollate injection, ex- 
udate  cells  were  harvested  by  peritoneal  lavage.  Similar 
numbers of macrophages were recovered from the wild- 
type  and  the  IL-113-deficient  mice,  demonstrating  that 
macrophage recruitment to the peritoneal cavity can occur 
in the absence of this cytokine. 
PEC from wild-type, heterozygous, and IL-113-deficient 
mice were incubated for 4 h in the presence or absence of 
LPS. By Northern blotting, there was no detectable IL-l{3 
mRNA in LPS stimulated PEC from the IL-113-deficient 
mice (Fig. 1 c). IL-113 mRNA was present at an intermedi- 
ate level in LPS-stimnlated PEC from mice heterozygous 
for IL-I~ deficiency. Given that the mutant IL-113 gene 
carried alterations limited to exon 4, and that this exon is 
not known to affect expression of the IL-113 gene, we spec- 
ulate  that the  absence  of detectable  IL-113 transcripts  in 
IL-113-deficient mice represents dramatic destabilization of 
the IL-113 mtLNA rather than obliteration of IL-113 tran- 
scription.  Hybridization  with  an  IL-lot  eDNA  probe 
showed  indistinguishable  induced  levels  of LPS-induced 
IL-la transcripts  in wild-type, heterozygous, and IL-113- 
deficient mice Fig.  1 c).  This  confirmed that PEC  from 
IL-1l~-deficient mice retained responsiveness  to  LPS and 
that LPS-induced expression of IL-la was not dependent 
on expression of IL-113. 
Analysis of IL-1 biosynthesis by pulse-chase labeling and 
immunoprecipitation  confirmed  that  IL-l{3  protein  was 
undetectable  in  mice  homozygous for  IL-I~  deficiency 
(Fig. 2 a). In contrast, biosynthesis ofpro-IL-la was indis- 
tinguishable in wild-type and IL-113-deficient mice (Fig. 2 
b).  In  normal LPS-stimulated macrophages,  induction of 
cdluhr apoptosis by treatment with 5 mM ATP is known to 
trigger efficient maturation of both IL-1 isoforms and their 
release  from the cell (41).  Consequently, we treated LPS- 
stimulated PEC from wild-type and IL-l~-deficient mice 
with ATP and evaluated the processing and release of IL-lot 
(Fig. 2, a and b). The ATP-induced release of mature IL-hx 
from wild-type and IL-l[3,-deficient cells was also indistin- 
guishable. This demonstrated that release of IL-la was not 
dependent on IL-I~. This is in contrast to data obtained in 
ICE-deficient mice in which in addition to the expected 
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IL-lot  IL-I~ 
pg / ml 
Wild-type 
Control  <15  <10 
LPS  <15  <10 
LPS/ATP  1,082 -+ 35  783 -+ 11 
IL-  1  [3--deficient 
Control  < 5  < 10 
LPS  106 +- 1  <10 
LPS/ATP  1,265  -+ 19  <10 
1 X 106 PEC were allowed to adhere overnight in a 12-well dish and 
treated with 1 I~g/ml LPS for 2 h. The cells were then washed and in- 
cubated either with ATP (5 mM) or with medium alone for 4 h. Then 
supernatants were collected and assayed in triplicate by ELISA. Data 
presented  are average levels of IL-1  _  SEM. Limits of detection  for 
IL-la and IL-1[3 were 15 pg/ml and 10 pg/ml, respectively. 
Figure 2.  Following stimulation with LPS for 2 h, thioglycollate-elic- 
ited PEC were pulse labeled with 3SS-methionine  for 30 rain, then treated 
with 5 mM ATP for 20 min. Supematants and lysates  were harvested at 
the indicated times of chase and immunoprecipitated with (a) anti-IL-l[3 
or (b) anti-IL-lct monoclonal antibodies. 
deficiency  of cellular processing  and  release  of IL-l[3  there 
was an unexpected reduction in the release of IL-lr~ (42). 
Finally,  IL-1  levels  in  the  supematants  of LPS-stirnu- 
lated,  ATP-treated  PEC  were  measured by ELISA  (Table 
1).  In  the  absence  of ATP,  neither  IL-la  nor  IL-I~ was 
detected in the supematants  of wild-type PEC.  Incubation 
with 5 mM ATP for 4 h  lead to the release from these cells 
of 1,082  pg/ml of IL-lot and 783 pg/ml of IL-l[3. No de- 
tectable  IL-l[3 was released from IL-l~-deficient  cells.  In 
contrast, IL-l~-deficient cells released 1,264 pg/ml of IL-l~t 
following treatment with LPS and ATP. 
Thus,  as  assessed  by  Northern  blotting,  pulse-chase  la- 
beling  and immunoprecipitation,  and ELISA,  gene  target- 
ing  resulted  in  complete  functional  ablation  of the  IL-I~ 
locus. All of the data suggested that normal expression and 
cellular  release  of IL-let were  retained.  This  distinguishes 
the biochemical characteristics of the IL-l~r-deficient strains 
from  ICE-deficient  strains  in  which  IL-I~ biosynthesis  is 
unaffected,  but  the  release  of IL-lct from activated  cells is 
substantially reduced  (42, 43). 
Unaltered  Sensitivity  to  Endotoxic  Shock  in  IL-lfl-defident 
Mice.  Treatment of normal mice with high doses ofendo- 
toxin  results  in  the  production  and  release  of several pro- 
inflammatory  cytokines,  including  TNF,  IL-1,  IL-6,  and 
IFN-~/. These, in turn,  appear to be the major mediators of 
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the lethal effects of endotoxin  (44). Blocking the  action of 
these cytokines reduces endotoxin-induced  mortality as evi- 
denced by endotoxin resistance in TNF receptor type 1-defi- 
cient  (45),  IFN-~/  receptor-deficient  (46),  and  ICE-defi- 
cient mice (42). In addition,  administration of the IL-lra to 
both mice (47)  and rabbits (48)  protects from the lethal ef- 
fects ofendotoxic shock. 
The sensitivity of IL-lJ3-deficient and wild-type mice to 
endotoxin  was  determined  both  with  pretreatment  with 
D-galactosamine (data not shown) and without galactosamine 
(Fig.  3).  Death  occurred  with  a  similar time course in the 
wild-type  and the  IL-l[3-deficient  animals.  The sensitivity 
of IL-lJ3-deficient  mice to endotoxin-induced  death  is  of 
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Figure 3. 
(open circles) and eight wild-type (closed  drdes) mice received 1.5 mg E. coli 
LPS (0127:B8) in sterile PBS by i.p. injection. 
Susceptibility to endotoxic shock. Groups of eight IL-lJ3  -/- interest in light of the defined resistance to endotoxin  con- 
ferred by treatment with the  IL-lra and by inherited  defi- 
ciency  of ICE.  As  ICE-deficient  and  IL-lra-treated  mice 
have defects in function of both IL-113  and IL-lot, whereas 
IL-l[3-deficient  mice  retain  IL-lct expression  and  release, 
these  data  support  a  significant  role for IL-loc in  systemic 
endotoxemia. 
IL-1~ Is Required  for Normal Contaa Hypersensitivity Re- 
sponses.  In order to test the role of IL-113 in contact hyper- 
sensitivity responses, we examined responsiveness in wild-type 
and  IL-l[3-deficient  mice  after  sensitization  with  varying 
concentrations  of TNCB.  Sensitization  of wild-type  mice 
with  25  p,1 of TNCB  ranging in concentration  from 0.01 
to  3.0%  lead in  a  dose-dependent  fashion  to  antigen-spe- 
cific swelling at the sight of challenge 24 h  after subcutane- 
ous  injection  of 10  mM  TNBS  into  the  footpad.  Signifi- 
cant footpad swelling was detected  after sensitization  with 
0.03% TNCB, and maximal swelling was observed after sen- 
sitization with 0.1% TNCB  (Fig. 4). In contrast, mice defi- 
cient in IL-1B showed no footpad swelling following sensi- 
tization with 0.1% TNCB, requiring  1% TNCB  to achieve 
a  response  equivalent  to  the  wild-type  mice.  Histological 
evaluation  of the  sites of antigen  challenge  showed an in- 
flammatory cell infiltrate in wild-type mice sensitized with 
0.1% TNCB  compared to nonsensitized  controls  (Fig.  5, a 
and b), but no detectable infiltrate in sensitized IL-l[3-defi- 
cient mice (Fig. 5 c). Similarly, when cells were isolated from 
the  axillary and  inguinal  lymph nodes  draining  the  site  of 
sensitization  and incubated  with  TNBS-haptenated  spleen 
cells,  dose-dependent  proliferation  was  detected  with  cells 
from wild-type mice sensitized with 0.1% TNCB, whereas 
no  specific  proliferation  was  detected  in  IL-l[3-deficient 
mice treated with this same concentration of sensitizing an- 
tigen  (Fig.  6).  Lymphocytes from nonsensitized  wild-type 
mice or wild-type mice sensitized with low doses of TNCB 
(0.01  and 0.03%)  did not proliferate in response to TNBS- 
haptenated  spleen  cells  (data  not  shown).  These  data  sug- 
gest, then, that the proliferative response in sensitized wild- 
type  mice  represented  T  cell  priming  in  vivo.  Together, 
these data all demonstrate  a significant defect in the  ability 
of IL-l[3-deficient  mice to manifest  a  contact  hypersensi- 
tivity reaction. 
Zheng  et  al.  previously  reported  that  in  an  indepen- 
dently  derived  IL-l[3--deficient  mouse  strain  the  contact 
hypersensitivity  response  to  oxazolone  was  normal  (28). 
We tested the response to topical oxazolone in the IL-I[3- 
deficient strain described  here.  Wild-type  and IL-l[3-defi- 
cient  mice  were  sensitized  by  topical  application  of ox- 
azolone (100 ml of 0.01%, 0.04%, 0.1%, 0.4%,  1%, and 4%) 
to the  shaved abdomen and 5  d  later sensitivity was tested 
by application of 50 p,1 of 1% oxazolone to the ear. After an 
additional  24  h,  the  degrees  of ear swelling were indistin- 
guishable in wild-type  and IL-l[3-deficient  mice  (data not 
shown).  These data are in dramatic contrast to results using 
TNCB  and  suggest  that  the  cutaneous  responses  to  these 
two antigens  are not equivalent.  Although  the mechanism 
remains undefined,  differences in the methods to elicit the 
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Figure  4.  Reduced  contact  hypersensitivity response in  IL-1[3  -/- 
mice. 8-12-week-old  IL-1B--deficient mice and their wild-type litter- 
mates were painted on their shaved abdomens with the indicated concen- 
trations of TNCB in 25  I~1 olive oil/acetone  (1:3). 5 d later, the mice 
were challenged by injection of 33 ml of 10 mM TNBS into the right 
footpad. PBS was injected into the left footpad. After 24 h, footpad swell- 
ing was measured. Solid bars, wild-type mice; hatched bars, IL-l[3-defi- 
cient mice. 
hypersensitivity  response  may  underlie  the  differences  in 
the TNCB  and the oxazolone responses.  For example, we 
measured hypersensitivity to TNCB  following injection  of 
soluble TNBS into the footpad, whereas hypersensitivity to 
oxazolone  was  measured  following  topical  application  to 
the ear. Thus,  the mechanism by which eliciting antigen is 
detected  in  the  footpad  and  the  ear may not  be identical. 
Additionally,  TNCB  was  applied  at the  time  of sensitiza- 
tion as a solution of 25% olive oil in acetone,  whereas ox- 
azolone was applied  dissolved in acetone alone.  Thus,  the 
local  handling  of the  sensitizing  antigen  may be  different 
for the  two  antigens.  Finally,  it  remains  possible  that  the 
cellular constituents  responsible for TNCB  and oxazolone 
reactivity are not the  same.  Regardless,  the  data presented 
here demonstrate  a dramatic requirement  for IL-113 in the 
response to TNCB. 
To investigate at which stage of the TNCB response IL-113 
exerted its action, we injected purified recombinant murine 
17 kD IL-113 (rlL-l[3) (49) intradermally immediately before 
sensitization at the site where the sensitizing antigen was to 
be  applied.  Pretreatment  with  rlL-l[3  but  not  with  saline 
resulted in dose-dependent  restoration of responsiveness to 
antigen challenge five days later (Fig. 7) and a restoration of 
the inflammatory cell infiltrate examined histologically (Fig. 
5 d). These data support a role for IL-113 specifically during 
the  sensitization  phase  of the  contact  hypersensitivity  re- 
sponse.  Sensitization  of the  IL-l[3-deficient mice is,  how- 
ever,  demonstrated  when  high  concentrations  of antigen 
are applied to the skin. We speculate that this indicates that 
IL-113  acts  on  or  through  cells  whose  role  is  to  enhance 
antigen  uptake,  processing,  or  delivery  to  the  antigen- 
responding cells and that high doses of antigen bypass these 
functions. 
1432  Impaired Contact Hypersensitivity in IL-l[3--deficient  Mice Figure 5.  Inflammatory  infiltrates in sections of footpad of TNBS-challenged mice. Mice sensitized by topical application of 0.1% TNCB or vehicle 
alone were challenged with 10 mM TNBS injected into the footpad. Tissue was harvested 24 h later, fixed in 10% neutral buffered  formalin, and sections 
stained with hematoxylin and eosin. (a) Wild-type mice mock-sensitized with vehicle alone; (b) wild-type mice sensitized with TNCB; (c) IL-l[3-defi- 
cient mice sensitized with TNCB; (at) IL-l[3-deficient mice treated intradermaUy  with 50 ng recombinant IL-I~ at the sensitization site immediately  be- 
fore application of  TNCB. 
Both Langerhans cells and keratinocytes have been shown 
to  express  IL-l[3 in  the  epidermis  (26,  27).  Using mono- 
nuclear phagocytes, we have  demonstrated  that induction 
of cellular apoptosis in vitro leads to rapid release ofbioac- 
tive IL-113 (41).  Our current data suggest either that these 
Langerhans  cells  or  keratinocytes  possess  a  novel  mecha- 
nism for IL-113 release that is expressed in situ in the skin, 
but not in vitro,  or that apoptosis of the IL-1 [3-producing 
cell is a characteristic  of contact hypersensitivity responses. 
Ahernatively, they may imply the presence of a novel IL-1 
receptor in skin that can interact with unprocessed 31  kD 
pro-IL-l[3 as an activating hgand,  or that may have speci- 
ficity for IL-113,  perhaps  not recognizing IL-loc A  prece- 
dent for a receptor that can discriminate IL-113 from IL-loL 
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Figure  6.  Absent  proliferative response to contact antigen in IL-I~- 
deficient mice. Lymphocytes were harvested ~om axillary and inguinal 
lymph nodes six days a~er sensitization with TNCB.  Proliferative re- 
sponses to mitomycin-C-treated TNP-haptenated sv129 spleen cells were 
measured as described in Methods. Data represent average +  SEM of 
triplicate determinations. Closed circles, wild-type mice; open circles, 
[L-lfl~-deficient  mice. 
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Figure 7.  Contact hypersensitivity can be restored by intradermal rIL- 
lB. The indicated amounts of recombinant routine II.-113  were injected 
intradermally at the sites of sensitization immediately before the applica- 
tion of 25 ml of 0.1% TNCB.  Challenge and measurement of footpad 
swelling were as described in Fig. 4. Closed bars, wild-type mice; hatched 
bars, IL-l~-deficient mice. 
comes from vaccinia virus where  a  secreted  II.-1  receptor 
with  specificity  for the  IL-1[3 isoform has  been  reported 
(50). 
Our observation that IL-l[3 plays a dramatic role in con- 
tact hypersensitivity responses to TNCB at low to moder- 
ate doses of sensitizing antigen caution against excluding an 
activity of this or any cytokine in a physiological response 
by experiments  using high levels of stimuli.  Although we 
have not  defined the  mechanism by which high  doses of 
sensitizing antigen overcome the defect in the contact hy- 
persensitivity response in IL-lJ3--deficient mice,  the use of 
low doses of sensitizing antigen may uncover a role for IL-113 
in lowering the  threshold  for responsiveness.  Conversely, 
high doses of sensitizing antigen may circumvent the fun- 
damental character of the response being analyzed. 
In summary, we report the generation of a mouse strain 
rendered  deficient in expression of IL-113  by gene  target- 
ing. This strain confirms that IL-1[3 is not required for via- 
ble embryonic development or normal post-natal growth. 
Analysis of this strain discloses no evidence of an obligatory 
role for IL-I~ in lymphoid cell development or in the de- 
velopment of other bone-marrow derived cells.  Addition- 
ally, absence of IL-113  does not alter the sensitivity to en- 
dotoxin-induced death in two models of endotoxic shock. 
Deficiency of IL-113 does,  however,  result  in  a  defect in 
contact hypersensitivity responsiveness to TNCB, with this 
effect  expressed  at  the  level  of sensitization.  Additional 
evaluation of this strain will permit definition of the cellular 
elements  in the  epidermis  that  mediate  this  effect.  It will 
also permit  definition of whether IL-1[3 acts selectively in 
the  epidermis,  or generally in sensitization  at all epithelial 
surfaces, particularly in the  respiratory  and  gastrointestinal 
tracts.  As  such,  this  IL-lj3-deficient  mouse  strain  may 
prove valuable in identifying new targets with clinical rele- 
vance to human hypersensitivity disease. 
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